Dr. Lesley A. Inker, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 181
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
MA license 221238 -
Internal Medicine Physician
MA license 221238
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tufts Medical Center Boston, MA
Medical groups
- Pratt Medical Group Inc (286 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 181
- Services billed
- 563
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 155 | 88 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 115 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 76 | 47 |
| Dialysis procedure including 1 evaluation | 51 | 15 |
| Hemodialysis procedure with physician evaluation | 34 | 22 |
| Hospital discharge day management, 30 minutes or less | 20 | 18 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 16 |
| New patient office or other outpatient visit, 45-59 minutes | 15 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 8 payments worth $10,033 in total to this clinician.
| AstraZeneca UK Limited | $5,175 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $4,858 |
| Consulting Fee | $10,033 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Dec 18, 2025 | Consulting Fee | $2,178 |
| Alexion Pharmaceuticals, Inc. Sep 17, 2025 | Consulting Fee | $1,340 |
| Alexion Pharmaceuticals, Inc. Jun 26, 2025 | Consulting Fee | $1,340 |
| AstraZeneca UK Limited May 15, 2025 | Consulting Fee | $1,250 |
| AstraZeneca UK Limited Jun 15, 2025 | Consulting Fee | $1,250 |
| AstraZeneca UK Limited Dec 19, 2025 | Consulting Fee | $1,005 |
| AstraZeneca UK Limited Feb 15, 2025 | Consulting Fee | $1,000 |
| AstraZeneca UK Limited Oct 9, 2025 | Consulting Fee | $670 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $591,767 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
Novartis Pharmaceuticals Corporation - A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)
Novartis Pharmaceuticals Corporation - A phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN
Alexion Pharmaceuticals, Inc. - Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.